microscopic polyangiitis


Also found in: Dictionary, Acronyms, Wikipedia.
Related to microscopic polyangiitis: polyarteritis nodosa

microscopic polyangiitis

systemic, nongranulomatous small-vessel vasculitis, associated with glomerulonephritis, pulmonary capillaritis, palpable purpura, and antineutrophil cytoplasmic autoantibodies.

microscopic polyangiitis

A systemic small-vessel vasculitis that primarily affects the kidneys, skin, and lungs of middle-aged men.

Clinical findings
Fever, malaise, myalgia, weight loss, and autoimmunity, including antineutrophil cytoplasmic antibodies (p-ANCA). Skin lesions occur in 30 to 50%, usually presenting as purpura due to leukocytoclastic vasculitis, less commonly as nodules involving the vessels of the dermis and subcutaneous fat and ulcers. The kidney shows rapidly progressive focal and segmental glomerulonephritis.

DiffDx
Polyarteritis nodosa.

microscopic polyangiitis

Hypersensitivity angiitis, microscopic periarteritis, microscopic polyarteritis Internal medicine The term recommended for necrotizing vasculitis with few or no immune deposits, affecting small vessels–ie, arterioles, capillaries, venules; MP is often accompanied by ANCA, necrotizing glomerulonephritis and pulmonary capillaritis. See Small vessel vasculitis, Systemic vasculitis.

mi·cro·scop·ic pol·y·an·gi·i·tis

(mī'krŏ-skop'ik pol'ē-an'jē-ī'tis)
Systemic, nongranulomatous small-vessel vasculitis, associated with glomerulonephritis, pulmonary capillaritis, palpable purpura, and antineutrophil cytoplasmic autoantibodies.
References in periodicals archive ?
Microscopic Polyangiitis (MPA) - Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Microscopic Polyangiitis (MPA) (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.
Renal biopsy showed necrotizing crescentic glomerulonephritis, leading to the diagnosis of microscopic polyangiitis (MPA).
KEYWORDS: ANCA associated vasculitis, Antineutrophil cytoplasmic antibodies (ANCA), Eosinophilic granulomatosis with polyangiitis, Granulomatosis with polyangiitis, Microscopic polyangiitis.
Subsequently, rituximab was approved in 2011 for the treatment of granulomatosis with polyangiitis (in which antineutrophil cytoplasmic antibodies and myeloperoxidase are involved) and microscopic polyangiitis (in combination with glucocorticoids).
Cevallos et al., "Microscopic polyangiitis: clinical and laboratory findings in eighty-five patients," Arthritis & Rheumatism, vol.
Segelmark, "Incidence and survival rates in Wegener's granulomatosis, microscopic polyangiitis, Churg-Strauss syndrome and polyarteritis nodosa," Rheumatology, vol.
Overall survival, renal survival and relapse in patients with microscopic polyangiitis: A systematic review of current evidence.
(1-9) This review focuses on coexisting/comorbid lung and renal disease encountered in AAV, including GPA, microscopic polyangiitis (MPA), and eosinophilic GPA (EGPA).
Severe microscopic polyangiitis with unilateral vocal cord paralysis as initial manifestation
interjectum cutaneous infection with surgical intervention alone in a patient with microscopic polyangiitis on chronic steroid and azathioprine therapy [17].
A p-ANCA by IIF and MPO positivity by ELISA are suggestive of microscopic polyangiitis (MPA).
Exclusion of ANCA associated vasculitis such as microscopic polyangiitis (MPA) and atypical presentations of giant cell arteritis (GCA) which may give rise to similar presentations is important when arriving at the correct diagnosis.

Full browser ?